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Abstract
Background: Noninvasive prenatal testing (NIPT) using massively parallel sequencing of cell-free DNA (cfDNA) is
increasingly being used to predict fetal chromosomal abnormalities. However, concerns over erroneous predictions
which occur while performing NIPT still exist in pregnant women at high risk for fetal aneuploidy. We performed
the largest-scale clinical NIPT study in Korea to date to assess the risk of false negatives and false positives using
next-generation sequencing.
Methods: A total of 447 pregnant women at high risk for fetal aneuploidy were enrolled at 12 hospitals in Korea. They
underwent definitive diagnoses by full karyotyping by blind analysis and received aneuploidy screening at 11–22
weeks of gestation. Three steps were employed for cfDNA analyses. First, cfDNA was sequenced. Second, the effect of
GC bias was corrected using normalization of samples as well as LOESS and linear regressions. Finally, statistical analysis
was performed after selecting a set of reference samples optimally adapted to a test sample from the whole reference
samples. We evaluated our approach by performing cfDNA testing to assess the risk of trisomies 13, 18, and 21 using
the sets of extracted reference samples.
Results: The adaptive selection algorithm presented here was used to choose a more optimized reference sample,
which was evaluated by the coefficient of variation (CV), demonstrated a lower CV and higher sensitivity than standard
approaches. Our adaptive approach also showed that fetal aneuploidies could be detected correctly by clearly splitting
the z scores obtained for positive and negative samples.
Conclusions: We show that our adaptive reference selection algorithm for optimizing trisomy detection showed
improved reliability and will further support practitioners in reducing both false negative and positive results.
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Background
In 1997 Lo et al. reported that Y-chromosome derived,
male, cell-free fetal DNA exists in maternal female blood
plasma and serum similar to tumor DNA using a poly-
merase chain method [1]. Since then, molecular screen-
ing of cell-free DNA (cfDNA) for detecting fetal
aneuploidy has generated much interest because aneu-
ploidy and other chromosome aberrations are fairly
common (nine out of 1,000 live births) [2]. As a result,
the discovery has inspired the development of many de-
tection methods [3]. However, the main obstacle in the
development of fast and low-cost diagnostic assays re-
mains the low fraction (<4 %) of cell-free, fetal DNA in
mothers [4]. Especially when cell-free fetal DNA is less
than 3.5 %, the number of unique DNA fragments in-
creases exponentially to retain the required aneuploidy
detection power [5]. In addition, detecting fetal
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aneuploidy at an early diagnostic stage is still difficult
because the fraction of original fetal DNA is propor-
tional to gestational age [6]. Earlier detection could
facilitate further diagnoses and actions. In twin pregnan-
cies, it is more difficult to detect fetal aneuploidy be-
cause the fetal fraction (FF) of an affected fetus may be
far lower than 4 % [7]. FF could be reduced by 50 %
owing to the proportion of a second normal fetus.
A high risk of fetal aneuploidy has been identified by
the first or second trimester screening, including mater-
nal age, ultrasound and maternal serum markers [8].
Women at high risk are subjected to invasive sampling
of fetal materials by amniocentesis for gestational age at
week 15 and by chorionic villus sampling for gestational
age at week 12 [9, 10]. However, these tests carry the
risk of iatrogenic pregnancy loss [11]. CfDNA screening,
on the other hand, offers two, major, clinical benefits
compared to invasive prenatal diagnoses: no risk of preg-
nancy loss and earlier detection. CfDNA screening does
have several limitations, such as requirements for further
invasive tests to confirm positive outcomes in the case
of discordant results that might arise from placental or
maternal cell mosaicism [12–14], the average size of
cfDNA being only around 150 base pairs (bp) [15] and
short half-life [16]. Even with these shortcomings,
sequencing-based, cfDNA screening using statistically
improved counting methods has risen in popularity
among pregnant women [17–19].
Since cfDNA screening for fetal aneuploidy was intro-
duced, reducing GC bias to detect aneuploidy with
higher sensitivities by reducing the coefficient of vari-
ation (CV) has become a key issue. Fan et al. [17], for
example, detected fetal aneuploidy initially by counting
the number of unique reads within each sliding window,
enabling clear separation of fetal trisomy outliers. They
successfully detected nine cases of trisomy 21 (T21), two
cases of T18, and one case of T13 in a cohort of 18
pregnancies by measuring sequence tag density relative
to the corresponding value of the genome DNA control
to remove GC bias representing the higher GC content.
Meanwhile, Chiu et al. suggested a method of detecting
fetal aneuploidy involving counting the unique reads
mapped to each chromosome and calculating z-scores
with the percentage of all the unique reads of each
chromosome for a sample [18]. They correctly detected
14 T21 fetuses and 14 euploid fetuses with z score > 3
without considering GC bias; however, the higher GC
content for chromosome X produced a smaller z score.
They also performed a large-scale validity study using a
previously established method that employs next-
generation sequencing to detect fetal trisomy 21 in high-
risk pregnancies with high accuracy. They detected
86 T21 fetuses with 100 % sensitivity and 97.9 % specifi-
city among 753 pregnancies [20]. Jiang et al. improved
cfDNA screening by employing GC-correlation to
minimize GC-bias and estimate the fraction of cell-free
fetal DNA as a key index to detect autosomal and sex
chromosome aneuploidies with high accuracy [5]. In a
total of 903 pregnancies, they detected autosomal aneu-
ploidies with 100 % sensitivity and 99.9 % specificity,
and sex chromosome aneuploidies with 85.7 % sensitiv-
ity and 99.9 % specificity by employing GC-correlation
and data normalization. Recently, Liao et al. [21], re-
ported a methodology used to systematically detect both
autosomal and sex chromosomal aneuploidies with high
accuracy. They employed an integrated method for GC
correction, which includes LOESS regression,
normalization and linear regression to reduce the effect
of GC bias in a total of 515.
Despite these advances, the risks of false negatives and
false positives still exist. In particular, cfDNA screening at
low or high risk for fetal trisomy generates more false nega-
tive and false positive results [21]. In this study, we designed
a new algorithm based on selecting reference samples adap-
tively according to the shared ranges of GC content and
DNA reads fraction of a test sample (The GC-related ter-
minologies used here were defined in Table 1).
Methods
Study participants and testing methods
From December 2014 through April 2015, 447 women
at high risk for fetal aneuploidy were enrolled into this
study from 12 hospitals (Mirae & Heemang, Namujung-
won, and GN and others in Korea). The characteristics
of the pregnant women are outlined in Table 2. The
mean maternal age was 35, and ranged from 25 to
42 years. The mean gestational age was 15 weeks, and
ranged from 11 to 22. Of these women, 29 were carrying
twins, and their features are outlined in Table 3. All 447
women endured invasive prenatal diagnostic testing
(amniocentesis) for fetal karyotyping, the results of
which were obtained by blind analysis. The institutional
review board at each participating hospital approved this
study. Written informed consent was obtained from all
participants.
All women underwent standard prenatal aneuploidy
screening using accredited clinical laboratories. First-
trimester screening includes the measurement of serum
pregnancy-associated plasma protein A, total or free
beta subunit of human chorionic gonadotropin (hCG),
and nuchal translucency. Second-trimester screening
comprises measuring maternal serum alpha-fetoprotein,
hCG, unconjugated estriol and inhibin A.
CfDNA preparation and maternal plasma DNA sequencing
About 10 mL of peripheral blood was collected from
each participant in a BCT™ tube (Streck, Omaha, NE,
USA). The blood sample was centrifuged at 1,200 × g for
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15 min at 4 °C. The plasma portion of blood was trans-
ferred to microcentrifuge tubes and centrifuged again at
16,000 × g for 10 min at 4 °C. CfDNA was extracted
from 1 mL of plasma using a QIAamp Circulating Nu-
cleic Acid Kit (Qiagen, Netherland). The end-repair of
the plasma cfDNA was carried out using T4 DNA poly-
merase, Klenow DNA polymerase, and T4 polymerase
kinase. DNA libraries for the Ion Proton sequencing sys-
tems were constructed according to the protocol
provided by the manufacturer (Life Technologies, SD,
USA). Proton PI Chip Kit version 2.0 was used to yield
an average 0.3× sequencing coverage depth per
nucleotide.
Data analysis
We used three processing steps for our comparative
cfDNA analyses. First, cfDNA was sequenced massively
using the Ion Proton system. All raw reads obtained
from the Ion Torrent Suite Software (Life Technologies)
were trimmed from the 3′ end using a sequencing qual-
ity threshold value of 20 (Q score) and filtered by a read
length threshold of 50 bp. The remaining reads were
aligned to the human genomic reference sequences
(hg19) using BWA [22]. Duplicate DNA reads were fil-
tered out by the Picard program (http://broadinstitute.-
github.io/picard/). Second, the effect of GC bias was
reduced using LOESS regression [23], normalization of
samples [5] and linear regression [24]. Each chromo-
some was divided into bins of 20 kb. After LOESS cor-
rection [24], given the corrected unique reads (RCij) on
chromosome j of sample i, the fraction of reads (Rf ij0 )




normalization of samples was calculated as follows: Rf i′j′
¼ Rf ij0 =
XN
i¼1
Rf ij0 . The final step was to perform a statis-
tical analysis after selecting reference samples adapted to
a test sample from all the reference samples [24]. The
full linear regression model was established based on
Table 1 GC-related terminologies
Terminologies Definition
GC content The percentage of guanine and cytosine
nitrogenous bases
GC content of a
sample
The GC content of all unique reads of each
chromosome of a sample, which are mapped to
the corresponding chromosome of the reference
genome
GC range The range of GC content of a sample
Unit value of GC
content
A unit value used to increase or decrease the
range of GC content of each chromosome of a
sample (default = 0.001)
The GC value of a
test sample
The GC content of all unique reads of each
chromosome of a test sample
Reads fraction of a
sample
The percentage of all unique reads of each
chromosome of a sample, which are mapped to
each corresponding chromosome of reference
genome
Unit value of reads
fraction
A unit value used to increase or decrease the
range of reads fraction of each chromosome of a
sample (default = 0.00005)
The RF value of a
test sample
The reads fraction value of all unique reads of
each chromosome of a test sample, which was
determined by fitting predicted fraction of reads
calculated as Rf
0
i′ j′ ¼ αþ β GCi′ j′ from all
reference samples
Table 2 Demographic characteristics in 447 pregnancies.
Demographic characteristics of 447 pregnant women in 12
hospitals in Korea
Characteristic Value
No. of patients 447
Maternal age - year
Mean 35
Range 20 ~ 46
Gestational age - week
Mean 15
Median 16
Range 11 ~ 22
Pregnancy trimester - no. (%)
First: 1–13 week gestation 137 (30.6)
Second: 14–26 week gestation 310 (69.4)
Male fetus - no. (%) 249 (52.5)
Female fetus - no. (%) 225 (47.5)
Table 3 Demographic characteristics in 29 twin pregnancies.
Demographic characteristics of 29 twin pregnancies from 12
hospitals in Korea
Characteristic Value
No. of patients with twins 29
Maternal age - year
Mean 35
Range 22 ~ 43
Gestational age - week
Mean 14
Median 13
Range 11 ~ 21
Pregnancy trimester - no. (%)
First: 1–13 week gestation 16 (55.2)
Second: 14–26 week gestation 13 (44.8)
Male fetus - no. (%) 26 (48.1)
Female fetus - no. (%) 28 (51.9)
Two patients with unknown fetal sex were excluded
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equation, Rf i′j′ ¼ αþ β GCi′j′ þ e where GCi′j′ was
the GC content of chromosome j’ of sample i’, β was the
coefficient factor between the fraction of reads and GC
content, and e was the error term. Fitting of the predicted
fraction of reads was calculated as Rf
0
i′j′ ¼ αþ β GCi′j′ .
The residual obtained by the equation R ¼ Rf i′ j′−Rf
0
i′j′
was fitted to a normal distribution and was used to derive a
z score for fetal aneuploidies [24].
Optimally adaptive reference samples were extracted
from all reference samples belonging to a shared range of
the GC content and the reads fraction of a test sample as
shown in Additional file 1: Figure S1. The GC content
range in this study was set from −0.001 to +0.001 as a step-
ping unit value when setting the GC content of a test sam-
ple as the median. The reads fraction range was set from
−0.00005 to +0.00005 as a stepping unit value when setting
the reads fraction of a test sample as the median, which
was determined by the fitting predicted fraction of reads
calculated as Rf
0
i′ j′ ¼ αþ β GCi′j′ from all reference
samples. The representative sample in each test group of
samples was selected and used to generate a set of refer-
ence samples increasing by 0.001 in GC content and by
0.00005 in reads fraction. By adjusting the unit value of GC
content or reads fraction, the resolution of sets of reference
samples could be changed. That is, a smaller unit could
make more conservative ranges of sets, while a larger unit
could make less conservative ranges of sets. In this study,
changes of 0.001 in GC content and 0.00005 in reads frac-
tion were set as the default stepping unit values.
We reasoned that a suboptimal threshold could result
from a suboptimal reference sample collection that is not
adapted statistically optimally to the test sample. Therefore,
we tried to collect a set of more optimized, or “adaptive”,
reference samples. First, the positive samples in 0.01 inter-
vals of GC content value were categorized into four groups
of 0.41, 0.42, 0.43, and 0.44 GC content regions. This was
to efficiently collect adaptive reference samples before ex-
tending a shared range of the GC content and the reads
fraction of a test sample using the unit value of GC content
or reads fraction. Thus, the two positive test samples in the
0.41 GC content region, the five positive test samples in the
0.42 region, the two positive test samples in the 0.43 region,
and the four positive test samples in the 0.44 region were
clustered according to the GC regions, respectively. Second,
if a sample size was >2, the median G +C content in each
group was chosen as the representative test sample. If there
were only 2 samples in a group, a representative was arbi-
trarily chosen. Third, the representative sample was used to
generate a set of reference samples by increasing the GC
content by 0.001 and the reads fraction by 0.00005. This
sets the common region shared with the GC content of the
representative sample ± 0.001 and the reads fraction of the
representative sample ± 0.00005, to generate a set of refer-
ence samples from the shared region. We repeated this to
extend the reads fraction of the representative sample by
±0.0001 (increasing an absolute unit value of reads fraction)
until the reads fraction reached the preset threshold
(±0.001). We repeated this after extending the GC content
of the representative sample by ±0.002 (increasing the abso-
lute unit value of GC content) until the GC content
reached the preset threshold (±0.02). Finally, sets of opti-
mized reference samples were selected by checking the
CVs, which were used to evaluate the quality of the set of
reference samples.
A z score > 3 indicated the fraction of chromosome
reads greater than that of the 99.9th percentile of the set
of the reference samples for a one-tailed distribution
[18]. We evaluated our method by performing cfDNA
testing to assess the risk of trisomies 21, 18, and 13.
Results
From 447 plasma samples with existing karyotyping diag-
noses, we showed that the adaptive selection strategy of
reference samples produced a more reliable and robust re-
sult than the previous approach of using all reference sam-
ples. There were 13 fetuses with T21 (including three twin
samples), one fetus with T18 in a twin pregnancy, one
fetus with T13, and two fetuses with XXY. Seventeen sam-
ples with aneuploidy, 29 samples with twins, and five sam-
ples recognized as outliers were excluded from 447
samples to produce more reliable reference samples. Thus,
we compared the adaptive selection method with the non-
adaptive selection method using 396 reference samples.
An average of approximately 7.4 ± 2.1 million raw reads
were obtained per sample. When sequence reads mapped
to only one genome location in the reference human gen-
ome, they were termed unique reads. Approximately
44.6 %, or 3.3 million unique reads, of the total raw reads
were retained. The distribution of GC contents of these
396 samples ranged from 40 % to 51 %. The CV to evalu-
ate the performance between the traditional and new
methods were used.
As shown in Additional file 1: Figure S2, GC correc-
tion played an important role in reducing the CV. Bars
represent the CV for chromosomes 13, 18, and 21 with
and without LOESS-based GC correction among refer-
ence samples (n = 396). However, despite the GC correc-
tion of the samples, Fig. 1 shows that the threshold is
still suboptimal in separating positive and negative re-
sults using a traditional method for chromosome 21 per-
haps due to suboptimal reference samples. Figure 2
shows the CV for chromosome 21 with and without
adaptive sample selection using a representative sample
with a GC = 0.424. Every CV for the adaptive approach
was lower than those for the baseline approach. There-
fore, the adaptive approach provided higher sensitivity
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for T21. In fact, Fig. 3 shows the clear thresholds ob-
tained using the six sets of adaptively selected samples.
One, a representative test sample, of five T21 samples
containing GC contents in the 0.42 region was used to
select adaptive samples according to a GC range and a
reads fraction range of the representative sample. The
remaining four T21 samples were used to evaluate posi-
tive results using the six sets. We also selected six sets
of the euploid samples within 0.424 ± 0.001 to evaluate
negative results.
Figures 4 and 5 show similar results with adaptive
sample selection using a representative sample with a
GC = 0.437. In addition, Additional file 1: Figure S3.1
and Additional file 1: Figure S3.2, using a representative
sample with a GC = 0.416, and Additional file 1: Figure
S4.1 and Additional file 1: Figure S4.2, using a represen-
tative sample with a GC = 0.446, show similar results to
our adaptive sample selection. As we had only one T18
and one T13 sample, we could not test these results
using other T18 and T13 samples. However, we found
that only one T18 or T13 reference could generate a
good set of adaptively selected samples to clearly separ-
ate the z scores obtained for positive and negative sam-
ples (Additional file 1: Figure S5 and Additional file 1:
Figure S6). A significant linear model was set up to
analyze the relationship of the reads fractions and the
GC contents of samples (Additional file 1: Figure S7).
Notably, we correctly detected three T21 and one T18
aneuploid samples in twin pregnancies. Currently, it re-
quires an FF of at least 4 % to get reliable results for ac-
curate cfDNA analyses [20, 25–30]. In our twin
pregnancies, three positive T21 results were dizygotic
twin pregnancies and one positive T13 result was a
monozygotic twin pregnancy. Therefore, the three posi-
tive results could have been false negatives because the
FF of the affected fetus could be below the 4 % thresh-
old. Instead of determining FF in this study, we used the
z score of aneuploid chromosomes, which shows a posi-
tive correlation with FF [24] as it is difficult to determine
FF precisely. Notably, setting cutoff values of the z score
as 2 for a negative result and 4 for a positive result
showed that the specific results of this study satisfied the
criteria (Fig. 3; f, Fig. 5; d, e).
Discussion
We have noted that the number of unique reads is cor-
related statistically with the GC content [5]. Therefore,
obtaining robust results for fetal aneuploidy detection
suggests the hypothesis that the GC content of the sam-
ple under test belongs to the range of GC contents of
the reference samples. The reason for this being that the
key criteria for detecting fetal aneuploidy in a test sam-
ple is the fitting of the predicted value from the refer-
ence samples. Thus, the predictability of the state of the
test sample depends on the statistical state of the refer-
ence samples. Therefore, we applied this concept to de-
tect fetal aneuploidies by selecting the reference samples
adaptively according to the GC content of a test sample.
We observed that in the process of selecting adaptive
reference samples, the range of the reads fraction of a
test sample is important to the collection of suitable ref-
erence samples. Therefore, we investigated the adaptive
reference samples belonging to the shared region of a
GC content value and a reads fraction value.
Fig. 1 Z scores obtained using the previous method. Z scores
obtained for each sample along with the ambiguous threshold
obtained using the previous method for chromosome 21 using
reference samples (n = 396)
Fig. 2 Coefficient of variation (CV) for chromosome 21 with and without
adaptive sample selection using the representative sample with a
GC= 0.424. The baseline bar represents the coefficient of variation used to
measure the genomic representation of chromosome 21 among
reference samples (n= 396) without adaptive sample selection. Additional
bars represent the CV with adaptive sample selection. The bar marked A
represents the coefficient of variation used to measure the genomic
representation of chromosome 21 among selected reference samples
(n= 37). The B (n=210), C (n= 120), D (n= 166), E (n= 226), and F
(n= 278) also represent the CV with various numbers of
reference samples
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In earlier studies, cfDNA screening for fetal aneu-
ploidy was performed successfully using smaller sized,
reference samples [17, 18]. Fan et al. [17] successfully
detected 12 fetal aneuploidies by counting the number
of unique reads within each sliding window and separat-
ing the outliers of fetal trisomy clearly with six reference
samples using the higher sample GC contents of (range,
42 % to 50 %). The GC distribution of these samples was
very similar to the GC distribution of our 396 reference
samples (GC range, 40 % to 51 %). We investigated why
the previous method did not detect fetal aneuploidy cor-
rectly, although it used a comparatively large number (n
= 396) of reference samples. Considering the distribution
of reads fractions vs. GC contents of samples as shown
in Additional file 1: Figure S7, we hypothesized that the
reason was the unbalanced distribution of the reads frac-
tions of samples according to the increasing GC content
values, especially at higher GC contents. On the other
hand, Liao et al. [24] detected aneuploidies with high ac-
curacy in 515 pregnancies (GC range, 38 % to 42 %) with
a comparatively balanced distribution of reads ratios vs.
GC contents of samples. Nevertheless, their results also
had borderline values of the z scores of chromosome 21
for positive and negative samples. This means that the
quality of a set of reference samples is more important
than the sample size. Until now, mainstream cfDNA
Fig. 3 Z scores obtained in the a, b, c, d, e, and f sets of adaptive reference samples generated using the adaptive method. Z scores obtained for
each sample along with the unambiguous thresholds using the adaptively selected samples represented in Fig. 2 are shown. The study included
five T21 samples containing GC contents of the 0.42 region. The first (a representative test sample) was used to select adaptive samples
according to a GC range and a reads fraction range of the representative sample. For example, 0.004 and 1e-05 represent a GC range and a reads
fraction range of the representative sample, respectively, in the A set of adaptive reference samples. The others were used to test positive results
using the adaptive reference samples. The euploid samples within 0.424 ± 0.001 were selected to test negative results
Fig. 4 Coefficient of variation (CV) for chromosome 21 with and
without adaptive sample selection using the representative sample
with a GC = 0.437. The baseline bar represents the coefficient of
variation used to measure the genomic representation of
chromosome 21 among reference samples (n = 396) without
adaptive sample selection. Additional bars represent the CV with
adaptive sample selection. The bar marked A represents the
coefficient of variation used to measure the genomic representation
of chromosome 21 among selected reference samples (n = 31). The
B (n = 90), C (n = 138), D (n = 189), E (n = 227), and F (n = 292) also
represent the CV with increased numbers of reference samples
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screening has focused on the issue of reducing GC bias
by increasing the sample size. This study suggested an
adaptive selection approach to collect samples adaptively
according to the GC content of a test sample.
Although this approach was practically feasible in our
data for detecting chromosome 21 aneuploidy, an inde-
pendent, larger sample size is required to confirm our
results. A sufficiently large sample size is necessary to
decide how many reference samples would be required
to obtain sufficient evidence of the reliability and validity
of our results. In addition, although only one T18 or
T13 test sample could generate a good set of adaptively
selected samples (Additional file 1: Figure S5 and Add-
itional file 1: Figure S6), we need to confirm our results
by detecting T18 or T13 in independent positive sam-
ples, using the set of selected reference samples.
Conclusions
Using 447 samples, we developed a new adaptive
method of selecting reference samples according to the
combined values of the GC content and the reads frac-
tion of a test sample. The approach was compared with
the previous method using all reference samples in order
to detect fetal aneuploidy and demonstrated to be reli-
able and robust.
Additional file
Additional file 1: Figure S1 showed optimally adaptive reference
samples extracted from all reference samples. Figure S2 showed that GC
correction played an important role in reducing the CV. Figures S3.1,
S3.2, S4.1, S4.2, S5 and S6 represented similar results to our adaptive
sample selection. Figure S7 represented the relationship of the reads
fractions and the GC contents of samples. (DOCX 2063 kb)
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